Navigation Links
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Date:7/8/2008

onadotropin (hCG). The primary endpoint was ongoing pregnancy rate assessed at 10 weeks or more after embryo transfer. The number of oocytes retrieved was the co-primary endpoint. The incidence of ovarian hyperstimulation syndrome (OHSS) was similar between both groups, 7.0 percent in the corifollitropin alfa group (1.9 percent severe) and 6.3 percent in the follitropin beta group (1.3 percent severe).

About corifollitropin alfa

Corifollitropin alfa is being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program. The corifollitropin alfa regimen is being developed in a GnRH antagonist protocol.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to Earn Trust, Every Day with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for corifollitropin alfa. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factor
'/>"/>

SOURCE Schering-Plough Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
6. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Schering-Plough Reports Top-Line Results of the IDEAL Study
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
11. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
(Date:11/21/2014)... SUNNYVALE, Calif. , Nov. 20, 2014 /PRNewswire/ ... Study at the 2014 AAGL Global Congress demonstrates ... vaginal insert designed to provide bowel control. One of ... MD, Associate Professor and Division Chief of Urogynecology ... North Carolina, won an Award for Best Written ...
(Date:11/21/2014)... BEVERLY HILLS, Calif. , Nov. 20, 2014 ... Ken Eaton , the election of Anthony J. ... as President. Effective November 19, 2014, ... and member of the Board of Directors of Oxis International, ... J. Cataldo has been named Chief Executive Officer of ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
(Date:11/21/2014)... 21, 2014 M3 Global Research , ... professional panel, today announced two important leadership changes to help ... as President of Market Research, Americas and the promotion of ... , Ms. DasGupta joined M3 in 2011 and has ... Head of Sales. Roni has over 17 years of ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, ... pregnant are much more likely to have a child who ... But it looks like environment may play a greater ... "Mothers who are overweight teach behaviors, and those behaviors are ... a research fellow at the Framingham Heart Study, Boston University ...
(Date:11/21/2014)... (HealthDay News) -- Some people with cochlear implants experience ... when they undergo an MRI scan, a new study ... researchers, about 300,000 people worldwide have cochlear implants, devices ... are deaf or have severe hearing loss. There have ... implants when undergoing MRI. One expert said the ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 (HealthDay ... rules that will make it easier for everyone to know ... The proposed changes would expand the number of trials that ... -- a publicly accessible database, according to the U.S. National ... and Human Services. "This proposed rule would close ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Kidney donation ... do for another. And now a new study finds that ... life are benefiting from policies that give them priority on ... almost 6,300 of the 16,900 kidney transplants that took place ... supplied by the study researchers. At the time ...
Breaking Medicine News(10 mins):Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2
... LifeCare Holdings, Inc. (the,"Company") today announced its operating results ... Our net patient service revenue increased by $6.4 million, ... $88.8 million from $82.4 million,for the comparable period in 2007. ... than the same period in 2007., The increase in ...
... Patient safety in hospitals focus of 48 NQF-endorsed ... patient,safety remains a major hurdle in the United ... voluntary consensus standards focused on,measuring the performance of ... readmission, and prevention and care,of venous thromboembolism., ...
... - QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today that ... the land and building comprising its corporate headquarters and ... with the closing of the transaction, QLT will enter ... continue its operations., "We are very pleased that ...
... appear to help quality of life for lung cancer ... -- Adding chemotherapy to other treatments being giving to ... asbestos exposure, does not appear to improve either survival ... which is usually fatal, is a cancer of the ...
... Corporation,("Select") today announced results for its first quarter ... ended March 31, 2008, net operating revenues,increased 17.4% ... the same,quarter, prior year. Income from operations decreased ... the same quarter, prior year. Net income,decreased 47.9% ...
... Governor Paterson,s leadership in proposing prescription,drug marketing reform ... AARP strongly believes,New York has a paramount interest ... address the undue influence that,pharmaceutical companies have over ... but the treatment they receive., The reforms ...
Cached Medicine News:Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 4Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 5Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 6Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 7Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 8Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 9Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... VersaPulse® PowerSuite™ holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... leg position for the seated patient and helps ... foot/ankle at 90 degrees to the leg. The ... stand. Stockinette is pulled over the foot and ... a routine fashion. The cast stand is slipped ...
... provides the highest level of protection ... lead protective eyewear. Consistent lens ... allowed. Mfg supervised by Licensed and ... meet or exceed standards for optical ...
Medicine Products: